Registration No. 333-______
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
Under
THE SECURITIES ACT OF 1933
MIM Corporation
(Exact name of registrant as specified in its charter)
Delaware 05-0489664
(State or other jurisdiction (I.R.S. Employer Identification No.)
of incorporation)
One Blue Hill Plaza, Pearl River, New York 10965
(Address of Principal Executive Offices) (Zip Code)
1996 STOCK INCENTIVE PLAN
1996 NON-EMPLOYEE DIRECTORS STOCK INCENTIVE PLAN
(Full Title of the Plan)
Barry A. Posner, Esq.,
MIM Corporation,
One Blue Hill Plaza, Pearl River, New York 10965
(914) 735-3555
(Name, address and telephone number, including area code, of agent for service)
Approximate date of commencement of the proposed
sale to the public: From time to time after the
Registration Statement becomes effective.
Copies to:
Charles J. Downey III, Esq.
Finn Dixon & Herling LLP
One Landmark Square
Stamford, Connecticut 06901
(203) 325-5000
<TABLE>
<CAPTION>
- ------------------------------------------------------------------------------------------------------------------------------------
CALCULATION OF REGISTRATION FEE
====================================================================================================================================
Proposed Maximum Proposed Maximum Amount of
Title of Securities Amount Offering Aggregate Registration
to be Registered to be Registered Price Per Share Offering Price Fee
====================================================================================================================================
Common Stock,
<S> <C> <C> <C> <C>
$0.0001 par value............ 3,496,053 shares $4.62 (1) $16,166,070.15 (1) $4,898.81 (1)
====================================================================================================================================
</TABLE>
(1) Estimated in accordance with Rule 457(h) and Rule 457(c) solely for the
purpose of calculating the registration fee on the basis of the weighted
average of (i) $3.95 per share for 3,118,383 options granted to date under
the plans; and (ii) $10.19 per share for the remaining 377,670 shares,
which is the average of the high and low sales prices of the Common Stock
of the Registrant reported on the NASDAQ National Market on August 15,
1997.
<PAGE>
EXPLANATORY NOTE
MIM Corporation, a Delaware corporation (the "Company"), adopted the MIM
Corporation 1996 Stock Incentive Plan (as amended, the "Employee Plan") and the
MIM Corporation 1996 Non-Employee Directors Stock Incentive Plan (the "Directors
Plan") (collectively, the "Plans") in 1996. The shares of the common stock of
the Company, $0.0001 par value per share (the "Common Stock"), reserved for
issuance upon the exercise of options awarded pursuant to the Plans have not
been registered under the Securities Act of 1933, as amended (the "Act").
However, the Company has awarded options under the Plans pursuant to valid
exemptions from the registration requirements of the Act.
This Registration Statement is intended to register the following for
issuance by the Company:
1. 3,078,383 shares and 40,000 shares of Common Stock which may be
issued by the Company pursuant to the exercise of outstanding options
previously awarded under the Employee Plan and the Directors Plan,
respectively; and
2. 317,670 shares and 60,000 shares of Common Stock which may be
issued by the Company pursuant to the exercise of options that may be
subsequently awarded under the Employee Plan and the Directors Plan,
respectively.
Also, this Registration Statement, and the reoffer prospectus included
herein, is intended to register for reoffer and/or resale shares of Common Stock
that may be acquired in the future under the Plans by persons who may be
considered affiliates of the Company as defined by Rule 405 under the Act.
The materials constituting the reoffer prospectus have been prepared
pursuant to Part I of Form S-3, in accordance with General Instruction C to Form
S-8.
-2-
<PAGE>
REOFFER PROSPECTUS
MIM CORPORATION
Common Stock
($0.0001 Par Value)
Up To 3,496,053 Shares
This Prospectus relates to the resale of up to 3,496,053 shares of Common
Stock, $0.0001 par value ("Common Stock"), of MIM Corporation (the "Company")
which may in the future be issued pursuant to the exercise of options awarded to
date, and which in the future may be awarded, under the Company's 1996 Stock
Incentive Plan (as amended, the "Employee Plan") and the Company's 1996
Non-Employee Directors Stock Incentive Plan (the "Directors Plan" and, together
with the Employee Plan, the "Plans") to, and which may be offered for resale
from time to time by, certain employees and directors of the Company and its
subsidiaries named in Annex I hereto (the "Selling Shareholders").
The Company will not receive any of the proceeds from the sale of the
Common Stock offered hereby (hereinafter, the "Securities"). The Company will
pay all of the expenses associated with the registration of the Securities and
this Prospectus. The Selling Shareholders will pay the other costs, if any,
associated with any sale of the Securities.
The Common Stock is quoted on the NASDAQ National Market under the symbol
"MIMS." On August 15, 1997 the last reported sale price per share of the Common
Stock, as quoted on the NASDAQ National Market, was $10.375.
See "Risk Factors" on page 3 for a discussion of certain risk and other
factors that should be considered by prospective investors.
----------
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES
AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE
COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY OR
ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL
OFFENSE.
----------
The date of this Prospectus is August 19, 1997.
<PAGE>
AVAILABLE INFORMATION
The Company has filed a Registration Statement on Form S-8 (the
"Registration Statement") with the Securities and Exchange Commission (the
"Commission") under the Securities Act of 1933, as amended (the "Securities
Act"), covering the securities (i) covered by this Prospectus, (ii) issuable
upon the exercise of options previously awarded under the Plans, and (iii)
issuable upon the exercise of options which may be subsequently awarded under
the Plans. This Prospectus omits certain information and exhibits included in
the Registration Statement, copies of which may be obtained upon payment of a
fee prescribed by the Commission or may be examined free of charge at the
principal office of the Commission in Washington, D.C.
The Company is subject to the informational requirements of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), and in accordance
therewith files reports, proxy statements and other information with the
Commission. Such reports, proxy statements and other information filed with the
Commission by the Company can be inspected and copied at the public reference
facilities maintained by the Commission at 450 Fifth Street, N.W., Washington,
D.C. 20549, and at the regional offices of the Commission located at Northwest
Atrium Center, 500 West Madison Street, Room 1400, Chicago, Illinois 60661-2511
and at Seven World Trade Center, New York, New York 10048. Copies of such
material can be obtained from the Public Reference Section of the Commission at
450 Fifth Street, N.W., Washington, D.C. 20549, at prescribed rates. Copies of
such material may also be obtained from the Commission's website, located at
http://www.sec.gov.
INCORPORATION BY REFERENCE
The following documents of the Company heretofore filed with the Commission
are hereby incorporated herein by reference:
(a) The Company's Annual Report on Form 10-K for the fiscal year ended
December 31, 1996, filed pursuant to Section 13(a) or 15(d) of the
Exchange Act;
(b) The Company's Quarterly Report on Form 10-Q for the fiscal quarter
ended March 31, 1997, filed pursuant to Section 13(a) or 15(d) of the
Exchange Act;
(c) The Company's definitive proxy statement dated May 8, 1997
prepared in connection with the Company's Annual Meeting of Stockholders
held on June 19, 1997 filed pursuant to Section 14 of the Exchange Act;
(d) The Company's Quarterly Report on Form 10-Q for the fiscal quarter
ended June 30, 1997, filed pursuant to Section 13(a) or 15(d) of the
Exchange Act; and
(e) The description of the Company's Common Stock contained in the
Company's Registration Statement on Form 8-A, filed pursuant to Section
12(g) of the Exchange Act on July 30, 1996, as amended by Form 8-A/A filed
on August 1, 1996, and declared effective on August 14, 1996.
All reports and other documents subsequently filed by the Company pursuant
to Sections 13(a) and 13(c), 14 and 15(d) of the Exchange Act, prior to the
filing of a post-effective amendment which indicates that all securities offered
hereunder have been sold or which deregisters all such securities then remaining
unsold shall be deemed to be incorporated by reference herein and to be a part
hereof from the date of filing of such reports and documents. Statements made
herein as to the contents of any contract, agreement or other document are not
necessarily complete. With respect to each such contract, agreement or other
document filed as an exhibit to the Registration Statement, reference is made to
the exhibit for a more complete description of the matter involved, and each
such statement shall be deemed qualified in its entirety by such reference.
2
<PAGE>
COMPANY
The Company is a pharmacy management organization that provides a broad
range of services to the pharmaceutical health care industry designed to promote
the cost-effective delivery of pharmacy benefits to the public. The Company
targets organizations involved in three key industry segments -- sponsors of
public and private health plans (such as HMOs and other managed care
organizations), retail pharmacies and pharmaceutical manufacturers and
distributors -- and offers services providing financial benefits to each of
them. The Company works with plan sponsors and local health care professionals
to design, implement and manage innovative pharmacy benefit management ("PBM")
programs to control pharmacy benefit costs under the plans, primarily through
financial risk sharing arrangements and clinically appropriate substitution of
generic drugs for equivalent but more expensive brand name drugs. The Company
offers suppliers of generic drugs the potential to increase sales and market
share through "preferred generic" marketing programs to participating pharmacies
and increases in generic drug utilization encouraged by the Company's PBM
programs. In turn, retail pharmacies receive financial incentives for supporting
the Company's PBM and preferred generics programs as well as discounts on drug
purchases and other management and support services.
The Company was incorporated in Delaware in March 1996 for the purpose of
combining the businesses and operations of Pro-Mark Holdings, Inc. and MIM
Strategic Marketing, LLC, which became 100% and 90% owned subsidiaries,
respectively, of the Company in May 1996. The Company completed its initial
public offering in August 1996. The Company's principal executive offices are
located at One Blue Hill Plaza, Pearl River, New York 10965, and its telephone
number is (914) 735-3555.
RISK FACTORS
An investment in the Common Stock offered hereby involves a high degree of
risk. Prospective investors should consider carefully the following risk
factors, in addition to the other information contained in this Prospectus,
including documents incorporated herein by reference, before purchasing the
securities offered hereby.
Limited Operating History; Risk of Managing Growth
The Company commenced its operations in June 1993 and has had a limited
operating history. There can be no assurance that the Company will be able to
continue to expand its market presence in current locations or successfully
enter other markets. Further, in order to manage growth effectively the Company
will need to continue to improve its systems and hire, train and manage
additional employees. If the Company is unable to manage its growth effectively,
the Company's business and results of operations could be adversely affected.
Dependence on RxCare Relationship
The Company has derived most of its revenue to date pursuant to an
agreement with RxCare of Tennessee, Inc. ("RxCare"), a pharmacy services
administrative organization owned by the Tennessee Pharmacists Association
representing approximately 1,200 retail pharmacies in Tennessee. Under the
RxCare agreement, the Company is obligated to operate and manage pharmacy
benefit programs for health plan sponsors that have entered into contracts with
RxCare for such services. RxCare reasonably may decline to execute any contract
with plan sponsors or pharmacies, or any amendment or renewal thereof,
negotiated by the Company on behalf of RxCare. A number of RxCare's contracts
with plan sponsors are for providing state-mandated pharmacy benefits to
formerly Medicaid-eligible (as well as certain uninsured and uninsurable)
Tennessee residents under the TennCare program, a so-called "Medicaid waiver"
state health program. Revenues from three of such TennCare contracts accounted
for approximately 76% of the Company's revenues during 1996. The Company
believes that the loss of its arrangement with RxCare, the loss of one or more
of such contracts, the termination or expiration of the TennCare program (which
is currently scheduled to expire on December 31, 1998) or the loss of funding
thereunder would have a material adverse effect on the Company's business and
results of operations.
3
<PAGE>
Limited Term of Material Agreements
The Company's contract with RxCare is scheduled to expire in December 1998
unless renewed in accordance with its terms. RxCare's contracts with plan
sponsors typically have a one-year term and are subject to automatic renewal
unless notice of termination is given. Those contracts are subject to earlier
termination upon the occurrence of certain events, including a breach of the
agreement which is not cured within 30 days of notice, insolvency or termination
of the TennCare program or of the plan sponsor's contract with the State of
Tennessee. There can be no assurance that RxCare's contracts with plan sponsors
or the Company's contract with RxCare will be continued or renewed in accordance
with their terms. The loss of any of such contracts could have a material
adverse effect on the Company's business and results of operations.
Capitated Agreements
A substantial portion of the Company's revenue have been derived from
"capitated" agreements, through which the Company receives a pre-determined fee
each month for each member enrolled in a particular health plan in return for
providing certain covered pharmacy services to plan members. The Company
generally negotiates the capitation fee for a particular plan (or subset of
individuals within a plan) based upon a number of factors, including competitive
conditions within a particular market and the expected costs of providing the
covered pharmacy services. The cost of providing pharmacy services varies among
plan participants and groups and is affected by many factors, including
formulary design and compliance, generic substitution rate and payment
structure. Expected costs are generally based on prior experience with similar
groups and demographic data based on the population at large. Data with respect
to prior experience may not be available and, if available, may not be a
reliable indicator of the actual results for a particular plan. In addition, the
Company may be required to bear all or a portion of the costs of certain
newly-developed drugs, such as medications for the treatment of AIDS, the
existence or cost of which may not have been known at the time the capitation
fee for a particular plan was established. There can be no assurance that the
cost of providing pharmacy services will not exceed the capitation fee, either
per member or per plan, throughout the entire contract term.
Government Regulation
Various Federal and state laws and regulations affecting the healthcare
industry do or may impact the Company's current and planned operations,
including, without limitation, Federal and state laws prohibiting kickbacks in
government health programs (including TennCare), Federal and state antitrust and
drug distribution laws, and a wide variety of consumer protection, insurance and
other state laws and regulations. While management believes that the Company is
in substantial compliance with all existing laws and regulations material to the
operation of its business, such laws and regulations are subject to rapid change
and often are uncertain in their application. As controversies continue to arise
in the healthcare industry (for example, regarding the efforts of plan sponsors
and pharmacy benefit managers to limit formularies, alter drug choice and
establish limited networks of participating pharmacies), Federal and state
regulation and enforcement priorities in this area can be expected to increase,
the impact of which on the Company cannot be predicted. There can be no
assurance that the Company will not be subject to scrutiny or challenge under
one or more of these laws or that any such challenge would not be successful.
Any such challenge, whether or not successful, could have a material adverse
effect upon the Company's financial position and results of operations.
Violation of the Federal anti-kickback statute, for example, may result in
substantial civil and criminal penalties, as well as exclusion from the Medicare
and Medicaid (including TennCare) programs. Further, there can be no assurance
that the Company will be able to obtain or maintain any of the regulatory
approvals that may be required to operate its business, and the failure to do so
could have a material adverse effect on the Company's financial position and
results of operations.
Control by Management
The Company's directors and executive officers beneficially own in the
aggregate a majority of the Company's Common Stock. Accordingly, they
collectively are able to determine the outcome of virtually all corporate
actions requiring approval by the stockholders of the Company, including the
election of directors.
4
<PAGE>
Dependence on Senior Management
The Company's operations have been substantially dependent on the services
of John H. Klein (Chairman and Chief Executive Officer), E. David Corvese (Vice
Chairman and principal stockholder of the Company) and Richard H. Friedman
(Chief Operating Officer, Chief Financial Officer and Treasurer). The loss of
the services of one or more of these individuals would have a material adverse
effect upon the Company's business. Messrs. Klein, Corvese and Friedman each
have employment agreements with the Company which restrict the ability of such
officers to compete with the Company and its affiliates for a period of one year
following termination.
Non-Compete Covenant
In connection with his resignation from Zenith Laboratories, Inc. a
manufacturer and distributor of generic drugs ("Zenith"), in January 1996 Mr.
Klein agreed that he would provide consultative services to Zenith through
December 31, 1998 and that, until then, neither he, nor any business in which he
has a direct or indirect interest, will own, manage or be employed or engaged by
any business that is substantially competitive with any material portion of the
business of Zenith or its subsidiaries as conducted in early 1996. Such covenant
may restrict the Company's ability to compete in certain areas including its
preferred generics business and any future drug distribution business.
Competition
The pharmacy benefit management and generic drug distribution businesses
are each highly competitive, and many of the Company's current and potential
competitors have considerably greater financial, technical, marketing and other
resources than the Company. The pharmacy benefit management business includes a
number of large, well capitalized companies with nationwide operations and many
smaller organizations typically operating on a local or regional basis. Some of
the larger organizations are owned by or otherwise related to a brand name drug
manufacturer and may have significant influence on the distribution of
pharmaceuticals. Numerous insurance and Blue Cross and Blue Shield plans,
managed care organizations and retail drug chains also have their own pharmacy
benefit management capabilities.
Professional Liability Risk
The services provided by the Company in connection with its business may
subject the Company to litigation and liability for damages. The Company
believes that its insurance protection is adequate for its present business
operations, but there can be no assurance that the Company will be able to
obtain and maintain insurance coverage in the future or that such insurance
coverage will be available on acceptable terms or adequate to cover any or all
potential professional liability, product liability or other claims. A
successful claim in excess of the Company's insurance coverage could have a
material adverse effect on the Company's business and results of operations.
Possible Negative Effects of Preferred Stock
The Company is authorized to issue 5,000,000 shares of Preferred Stock, the
designation, rights and preferences of which (including voting, dividend,
redemption and liquidation rights) may be fixed by the Company's Board of
Directors from time to time without further stockholder action. Shares of
Preferred Stock could be issued in the future with rights and preferences that
could make the possible takeover of the Company or the removal of management of
the Company more difficult or could otherwise adversely impact the rights of
holders of Common Stock.
No Intention to Pay Dividends
The Company presently intends to retain all earnings, if any, to support
the operation and expansion of its business and does not anticipate paying cash
dividends in the foreseeable future.
5
<PAGE>
Possible Volatility of Stock Price
The market price of the Common Stock has fluctuated substantially in recent
months. The price of the Common Stock may be subject to fluctuations in the
future in response to operating results, general market movements and other
factors. In addition, the stock market in recent years has experienced price and
volume fluctuations that often have been unrelated or disproportionate to the
operating performance of companies. These fluctuations, as well as general
economic and market conditions, may adversely affect the market price of the
Common Stock.
SELLING SHAREHOLDERS
The table attached as Annex I hereto sets forth, as of the date of this
Prospectus or a subsequent date if amended or supplemented, (a) the name of each
Selling Shareholder and his or her relationship to the Company during the past
three years; (b) the number of shares of Common Stock each Selling Shareholder
beneficially owns (assuming that all options to acquire shares are exercisable
within 60 days, although certain options actually vest over three years); (c)
the number of Securities offered pursuant to this Prospectus by each Selling
Shareholder; and (d) the amount and percentage of the Common Stock outstanding
to be held by such Selling Shareholder after giving effect to the Offering. The
information contained in Annex I may be amended or supplemented from time to
time.
USE OF PROCEEDS
The Company will not receive any of the proceeds from the sale of the
Securities offered hereby.
PLAN OF DISTRIBUTION
Sales of the Securities offered hereby may be made on the NASDAQ National
Market or the over-the-counter market or otherwise at prices and on terms then
prevailing or at prices related to the then current market price, or in
negotiated transactions. The Securities may be sold in (a) block trades in which
the broker or dealer so engaged will attempt to sell the Securities as agent but
may position and resell a portion of the block as principal to facilitate the
transaction, (b) transactions in which a broker or dealer acts as principal and
resells the Securities for its account pursuant to this Prospectus, (c) exchange
distributions in accordance with the rules of such exchange, and (d) ordinary
brokerage transactions and transactions in which the broker solicits purchases.
In effecting sales, brokers or dealers engaged by the Selling Shareholders may
arrange for other brokers or dealers to participate. Brokers or dealers will
receive commissions or discounts from the Selling Shareholders in amounts to be
negotiated immediately prior to sale. Such brokers or dealers and any other
participating brokers or dealers may be deemed to be "underwriters" within the
meaning of the Securities Act in connection with such sales and any discounts
and commissions received by them and any profit realized by them on the resale
of the Securities may be deemed to be underwriting discounts and commissions
under the Securities Act. There is no assurance that any of the Selling
Shareholders will offer for sale or sell any or all of the Securities covered by
this Prospectus.
INDEMNIFICATION OF DIRECTORS AND OFFICERS
The Company's Amended and Restated Certificate of Incorporation limits the
liability of the Company's directors to the Company or its stockholders to the
fullest extent permitted by the Delaware General Corporation Law (the "DGCL").
Specifically, directors of the Company will not be personally liable for
monetary damages for breach of a director's fiduciary duty as a director except
for liability (a) for any breach of the director's duty of loyalty to the
Company or its stockholders, (b) for acts or omissions not in good faith or
which involve intentional misconduct or a knowing violation of law, (c) for
unlawful payment of dividends or unlawful stock repurchases or redemptions as
provided in Section 174 of the DGCL or (d) for any transaction from which the
director derived an improper personal benefit. In addition, the Company's
By-Laws require the Company to indemnify any current or former director or
officer to the fullest extent permitted by the DGCL. The Company also maintains
insurance for the benefit of its directors and officers and the directors and
officers of its subsidiaries insuring such persons against liabilities,
including liabilities under the securities laws.
6
<PAGE>
LEGAL MATTERS
Certain legal matters will be passed upon for the Company by Finn Dixon &
Herling LLP, Stamford, Connecticut.
EXPERTS
The consolidated financial statements of MIM Corporation appearing in
Company's Annual Report on Form 10-K for the year ended December 31, 1996 have
been audited by Arthur Andersen LLP, independent auditors, as set forth in their
report thereon included therein and incorporated herein by reference. Such
consolidated financial statements are incorporated herein by reference in
reliance upon such report given upon the authority of such firm as experts in
accounting and auditing.
----------
7
<PAGE>
ANNEX I
SELLING SHAREHOLDERS (1)
<TABLE>
<CAPTION>
Shares Beneficially
Shares Shares Owned After Offering: (2)
Beneficially Offered -------------------------
Name Relationships to the Company Owned Hereby Number Percentage
---- ---------------------------- ----- ------ ------ ----------
<S> <C> <C> <C> <C> <C>
E. David Corvese Founder; Vice Chairman; Director 7,469,056(3) 1,336,950 6,132,106 47.2
Louis A. Luzzi Director 20,300(4) 20,000 300 *
Barry A. Posner Secretary; General Counsel 50,000(5) 50,000 -- --
Scott R. Yablon Director 20,000(5) 20,000 -- --
</TABLE>
* Less than one percent.
(1) Assumes that all options held by the listed individuals are exercisable
within 60 days, although certain options vest over a three year period.
Shares deemed beneficially owned by virtue of the right of an individual to
acquire them within 60 days upon the exercise of an option are treated as
outstanding for purposes of determining beneficial ownership by such
individual.
(2) Assumes the sale of all securities offered hereby. Based upon 13,002,747
shares of Common Stock outstanding on August 15, 1997.
(3) (i)Includes 5,460,000 shares owned by Mr. Corvese which are subject to
options granted by him to certain Company officers and directors (of which
options to purchase 4,220,000 shares are currently exercisable), (ii)
includes 1,336,950 shares issuable upon exercise of options granted by the
Company, and (iii) excludes the following shares, beneficial ownership of
which Mr. Corvese disclaims: 672,106 owned by Mr. Corvese's spouse and
978,841 shares owned by trustees for the benefit of various members of Mr.
Corvese's extended family.
(4) Includes 20,000 shares issuable upon exercise of an option.
(5) Consists of shares issuable upon exercise of options.
8
<PAGE>
NO DEALER, SALES REPRESENTATIVE OR ANY OTHER PERSON HAS BEEN AUTHORIZED TO
GIVE ANY INFORMATION OR TO MAKE ANY REPRESENTATION NOT CONTAINED IN THIS
PROSPECTUS IN CONNECTION WITH THIS OFFERING, AND IF GIVEN OR MADE, SUCH
INFORMATION OR REPRESENTATION MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED
BY THE COMPANY OR THE SELLING SHAREHOLDERS. THIS PROSPECTUS DOES NOT CONSTITUTE
AN OFFER TO SELL, OR A SOLICITATION OF ANY OFFER TO BUY, COMMON STOCK BY ANYONE
IN ANY JURISDICTION IN WHICH SUCH AN OFFER OR SOLICITATION IS NOT AUTHORIZED, OR
IN WHICH THE PERSON MAKING SUCH OFFER OR SOLICITATION IS NOT QUALIFIED TO DO SO,
OR TO ANY PERSON TO WHOM IT IS UNLAWFUL TO MAKE SUCH AN OFFER OR SOLICITATION.
NEITHER THE DELIVERY OF THIS PROSPECTUS NOR ANY SALE MADE HEREUNDER SHALL, UNDER
ANY CIRCUMSTANCES, CREATE AN IMPLICATION THAT THE INFORMATION CONTAINED HEREIN
IS CORRECT AS OF ANY TIME SUBSEQUENT TO ITS DATE.
----------
TABLE OF CONTENTS
Page
Available Information........................................................2
Incorporation By Reference...................................................2
Company......................................................................3
Risk Factors.................................................................3
Selling Shareholders.........................................................6
Use of Proceeds..............................................................6
Plan of Distribution.........................................................6
Legal Matters................................................................7
Experts......................................................................7
Annex I- Selling Shareholders................................................8
<PAGE>
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
There are hereby incorporated by reference in this Registration Statement
the following documents and information heretofore filed with the Securities and
Exchange Commission (the "Commission"):
(a) The Company's Annual Report on Form 10-K for the fiscal year ended
December 31, 1996, filed pursuant to Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, as amended (the "Exchange Act");
(b) The Company's Quarterly Report on Form 10-Q for the fiscal quarter
ended March 31, 1997, filed pursuant to Section 13(a) or 15(d) of the
Exchange Act;
(c) The Company's definitive proxy statement dated May 8, 1997
prepared in connection with the Company's Annual Meeting of Stockholders
held on June 19, 1997 filed pursuant to Section 14 of the Exchange Act;
(d) The Company's Quarterly Report on Form 10-Q for the fiscal quarter
ended June 30, 1997, filed pursuant to Section 13(a) or 15(d) of the
Exchange Act; and
(e) The description of the Company's Common Stock contained in the
Company's Registration Statement on Form 8-A, filed pursuant to Section
12(g) of the Exchange Act on July 30, 1996, as amended by Form 8-A/A filed
on August 1, 1996, and declared effective on August 14, 1996.
All reports and other documents filed by the Company pursuant to Sections
13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this
Registration Statement and prior to the filing of a post-effective amendment
which indicates that all securities offered have been sold or which deregisters
all securities then remaining unsold shall be deemed to be incorporated by
reference in this Registration Statement and to be part hereof from the date of
filing of such reports or documents. Statements made herein as to the contents
of any contract, agreement or other document are not necessarily complete. With
respect to each such contract, agreement or other document filed as an exhibit
to this Registration Statement, reference is made to the exhibit for a more
complete description of the matter involved, and each such statement shall be
deemed qualified in its entirety by such reference.
Item 4. Description of Securities.
Not applicable.
II-1
<PAGE>
Item 5. Interests of Named Experts and Counsel.
Not applicable.
Item 6. Indemnification of Directors and Officers.
The Company's Amended and Restated Certificate of Incorporation (the
"Certificate of Incorporation") limits the liability of the Company's directors
to the Company or its stockholders to the fullest extent permitted by the
Delaware General Corporation Law (the "DGCL"). Specifically, directors of the
Company will not be personally liable for monetary damages for breach of a
director's fiduciary duty as a director except for liability (a) for any breach
of the director's duty of loyalty to the Company or its stockholders, (b) for
acts or omissions not in good faith or which involve intentional misconduct or a
knowing violation of law, (c) for unlawful payment of dividends or unlawful
stock repurchases or redemptions as provided in Section 174 of the DGCL or (d)
for any transaction from which the director derived an improper personal
benefit. In addition, the Company's By-Laws (the "By-laws") require the Company
to indemnify any current or former director or officer to the fullest extent
permitted by the DGCL. The Company also maintains insurance for the benefit of
its directors and officers and the directors and officers of its subsidiaries
insuring such persons against liabilities, including liabilities under the
securities laws.
Item 7. Exemption from Registration Claimed.
Not applicable.
Item 8. Exhibits.
Exhibit
Number
------
4.1 Amended and Restated Certificate of Incorporation of the Company
(incorporated by reference to Exhibit 3.1 of the Company's
Registration Statement on Form S-1 (No. 333-05327 )).
4.2 By-laws of the Company (incorporated by reference to Exhibit 3.2
of the Company's Registration Statement on Form S-1 (No.
333-05327)).
4.3 The Company's 1996 Stock Incentive Plan, as amended (incorporated
by reference to Exhibit 10.32 of the Company's Annual Report on
Form 10-K for the fiscal year ended December 31, 1996).
4.4 The Company's 1996 Non-Employee Directors Stock Incentive Plan
(incorporated by reference to Exhibit 10.29 of the Company's
Registration Statement on Form S-1 (No. 333-05327)).
II-2
<PAGE>
Exhibit
Number
------
5.1* Opinion of Finn Dixon & Herling LLP as to legality of securities
being registered.
23.1* Consent of Arthur Andersen LLP.
23.2 Consent of Finn Dixon & Herling LLP (contained in Exhibit 5.1
hereto).
24.1 Power of Attorney (included on the signature pages).
-------------------------
*Filed herewith.
Item 9. Undertakings.
A. The undersigned registrant hereby undertakes:
(1) (i) To file, during any period in which offers or sales are being
made, a post-effective amendment to this registration statement to include
any prospectus required by Section 10(a)(3) of the Securities Act of 1933
(the "Securities Act");
(ii) To reflect in the prospectus any facts or events arising
after the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate,
represent a fundamental change in the information set forth in the
registration statement The foregoing notwithstanding, any increase or
decrease in volume of securities offered (if the total dollar value of
securities offered would not exceed that which was registered) and any
deviation from the low or high and of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission
pursuant to Rule 424(b) if, in the aggregate, the changes in volume and
price represent no more than a 20 percent change in the maximum aggregate
offering price set forth in the "Calculation of Registration Fee" table in
the effective registration statement; and
(iii) To include any material information with respect to the plan
of distribution not previously disclosed in the registration statement or
any material change to such information in the registration statement.
(2) That, for the purposes of determining any liability under the
Securities Act, each such post-effective amendment shall be deemed to be a
new registration statement relating to the securities offered therein, and
the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof.
II-3
<PAGE>
(3) To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the
termination of the offering.
B. The undersigned registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act, each filing of the
registrant's annual report pursuant to Section 13(a) or Section 15(d) of the
Exchange Act (and, where applicable, each filing of an employee benefit plan's
annual report pursuant to Section 15(d) of the Exchange Act) that is
incorporated by reference in the registration statement shall be deemed to be a
new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof.
C. Insofar as indemnification for liabilities arising under the Securities
Act may be permitted to directors, officers and controlling persons of the
registrant pursuant to the DGCL, the Certificate of Incorporation, the By-Laws
or otherwise, the registrant has been advised that in the opinion of the
Securities and Exchange Commission such indemnification is against public policy
as expressed in the Securities Act and is, therefore, unenforceable. In the
event that a claim for indemnification against such liabilities (other than the
payment by the registrant of expenses incurred or paid by a director, officer or
controlling person of the registrant in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling person
in connection with the securities being registered, the registrant will, unless
in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question of whether
such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue.
II-4
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant
certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-8 and has duly caused this Registration
Statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the Town of Pearl River, State of New York, on this 18th day of
August, 1997.
MIM Corporation
By: /s/ John H. Klein
John H. Klein, Chairman of the Board
and Chief Executive Officer
POWERS OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature
appears below constitutes and appoints John H. Klein and Richard H. Friedman
jointly and severally as his or her attorneys-in-fact, each with the power of
substitution, for him or her in any and all capacities, to sign any amendments
to this Registration Statement, and to file the same, with exhibits thereto and
other documents in connection therewith, with the Securities and Exchange
Commission, hereby ratifying and confirming all that each of said
attorneys-in-fact, or his substitute or substitutes, may do or cause to be done
by virtue hereof.
II-5
<PAGE>
Pursuant to the requirements of the Securities Act of 1933, this
Registration Statement has been signed by the following persons in the
capacities and on the dates indicated.
Signature Capacity(ies) Date
--------- ------------- ----
/s/ John H. Klein Principal Executive Officer / Director August 18,1997
- -----------------------
John H. Klein
/s/ Richard H. Friedman Principal Financial and Accounting August 18,1997
- -----------------------
Richard H. Friedman Officer / Director
/s/ E. David Corvese Director August 18,1997
- -----------------------
E. David Corvese
/s/ Leslie B. Daniels Director August 18,1997
- -----------------------
Leslie B. Daniels
/s/ Louis A. Luzzi Director August 18,1997
- -----------------------
Louis A. Luzzi
/s/ Scott R. Yablon Director August 18,1997
- -----------------------
Scott R. Yablon
II-6
Exhibit 5.1
FINN DIXON & HERLING LLP
ONE LANDMARK SQUARE
STAMFORD, CONNECTICUT 06901
Telephone: (203) 325-5000
Facsimile: (203) 348-5777
August 18, 1997
MIM Corporation
One Blue Hill Plaza
Pearl River, New York 10965
Re: MIM Corporation -- Registration Statement on Form S-8
Ladies and Gentlemen:
We have acted as counsel to MIM Corporation, a Delaware corporation (the
"Company"), in connection with the preparation and filing with the Securities
and Exchange Commission of a registration statement on Form S-8 (the
"Registration Statement") of the Company, covering 3,496,053 (the "Shares") of
the Common Stock, $0.0001 par value per share, of the Company, to be issued
pursuant to the Company's 1996 Stock Incentive Plan, as amended, and 1996
Non-Employee Directors Stock Incentive Plan (collectively, the "Plans").
In rendering the opinion set forth herein, we have examined executed
copies, telecopies or photocopies of: (1) the Registration Statement and the
Plans; (ii) the Amended and Restated Certificate of Incorporation of the
Company, the By-laws of the Company and exerpts from the minute books of the
Company; (iii) the current forms of Option Agreements used in connection with
the Plans; and (iv) such other records, documents, certificates and other
instruments as in our judgment are necessary or appropriate as a basis for the
opinion expressed below. In our examination of such documents we have assumed
the genuineness of all signatures, the legal capacity of natural persons, the
authenticity of all documents submitted to us as originals, the conformity to
original documents of all documents submitted to us as certified or photostatic
copies, and the authenticity of the originals of such copies. As to any facts
material to this opinion which we did not independently establish or verify, we
have relied upon statements and representations of officers and other
representatives of the Company.
Based upon the foregoing, and in reliance thereon, and subject to the
qualifications, assumptions and exceptions heretofore and hereinafter set forth,
we are of the opinion that upon the issuance of the Shares in accordance with
the
<PAGE>
- 2 -
Plans (and in accordance with the terms of any written options, option
agreements or other agreements which are issued or entered into pursuant to the
terms and conditions of the Plans) and as contemplated by the Registration
Statement, the Shares will be validly issued, fully paid and non-assessable.
We do not express, or purport to express, any opinion with respect to the
laws of any jurisdiction other than the laws of the State of Connecticut, the
General Corporation Law of the State of Delaware and the federal securities laws
of the United States of America.
We hereby consent to the filing of this letter as an exhibit to the
Registration Statement and further consent to the use of our name wherever
appearing in the Registration Statement and the reoffer prospectus dated the
date hereof which forms a part thereof. In giving this consent, we do not
thereby admit that we are in the category of persons whose consent is required
under Section 7 of the Securities Act of 1933, as amended, or the rules and
regulations promulgated thereunder by the Securities and Exchange Commission.
This opinion is given as of the date hereof and we assume no obligation to
update or supplement this opinion to reflect any facts or circumstances which
may hereafter occur or come to our attention or any changes in law which may
hereafter occur.
Very truly yours,
/s/ FINN DIXON & HERLING LLP
Exhibit 23.1
CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS
To MIM Corporation:
As independent public accountants, we hereby consent to the incorporation by
reference in this registration statement of our reports dated February 24, 1997
incorporated by reference in MIM Corporation's Form 10-K for the year ended
December 31, 1996 and to all references to our Firm included in this
registration statement.
ARTHUR ANDERSEN LLP
Roseland, New Jersey
August 14, 1997
